Clinical trial

Ondansetron as a Strategy for Reducing Propofol Injection Pain in Pediatrics: a Randomized Controlled Trial

Name
STUDY00001599
Description
This study is a randomized, single-site clinical trial that will take place at Children's Healthcare of Atlanta at Egleston. The investigators want to see if in pediatric patients, giving Zofran prior to propofol, reduces the pain that patients often experience when propofol is injected through an IV. Subjects will be randomized to 1 of 2 groups: lidocaine (common standard of care), or Zofran. The investigators hope to show a means of improving pain control in their patients undergoing anesthesia.
Trial arms
Trial start
2023-05-18
Estimated PCD
2024-12-01
Trial end
2024-12-01
Status
Recruiting
Phase
Early phase I
Treatment
Ondansetron
Ondansetron (Zofran) is a 5-hydroxytryptamine-3 (5-HT3) receptor antagonist commonly used to treat postoperative nausea and vomiting.
Arms:
Ondansetron premedication Group
Other names:
Zofran, Ondansetron hydrochloride
Lidocaine
Lidocaine is a local anesthetic agent used intravenously prior to the propofol injection. Currently the standard of care to help decrease the severity of pain in the injection site, a common side effect of propofol.
Arms:
Lidocaine premedication Group
Other names:
Xylocaine, lidocaine hydrochloride (HCl) Injection
Size
120
Primary endpoint
Change in verbal rating scale (VRS) form baseline
Baseline, during propofol injection (30 seconds)
Change in Motor score scale from baseline
Baseline, during propofol injection (30 seconds)
Eligibility criteria
Inclusion Criteria: * Patients 2 years old through 17 years of age * Children undergoing surgery at Children's Healthcare of Atlanta Egleston location * Patient with existing peripheral vascular access in the arm below the antecubital fossa * Patients with an American Society of Anesthesiologists (ASA) physical status category score of 1, 2 or 3 * Parent or legal guardian willing to participate, and able to understand and sign the provided informed consent * No known chronic pain syndrome Exclusion Criteria: * Parent or legal guardian unwilling to participate or unable to understand and sign the provided informed consent * Patients presenting for endoscopy procedures * Known chronic pain syndrome * Patient diagnosed with long QT syndrome * Patient weighing \>40kg * Documented allergy to study medications * Pain on injection of pre-operative normal saline flush * Patient has received an opioid within 30 minutes prior to anesthesia induction
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE2'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'PREVENTION', 'maskingInfo': {'masking': 'SINGLE', 'whoMasked': ['OUTCOMES_ASSESSOR']}}, 'enrollmentInfo': {'count': 120, 'type': 'ESTIMATED'}}
Updated at
2024-01-11

1 organization

2 products

1 indication

Organization
Emory University
Product
Lidocaine